Sparing the contralateral submandibular gland without compromising PTV coverage by using volumetric modulated arc therapy

Table 1 Patient characteristics

Patient	Site	subsite	TNM	stage	elective dose (Gy)	chemotherapy
1	oropharynx	tonsil	T4N2b	IV	57.75	TPF + carbo weekly
2	oropharynx	base of tongue	T3N0	III	57.75	CDDP 3x
3	oropharynx	tonsil	T3N0	III	57.75	cetuximab
4	oropharynx	tonsil	T2N2b	IV	57.75	CDDP weekly
5	oropharynx	tonsil	T4bN0	IV	57.75	TPF + CDDP weekly
6	oropharynx	base of tongue	T3N2b	IV	57.75	CDDP 3x
7	oropharynx	tonsil	T3N1	III	57.75	CDDP 3x
8	oropharynx	tonsil	T2N2b	IV	57.75	CDDP 3x
9	oropharynx	pharyngeal wall	T3N2b	IV	57.75	CDDP 3x
10	oropharynx	tonsil	T3N2b	IV	57.75	CDDP 3x
11	oropharynx	tonsil	T2N2b	IV	57.75	CDDP 3x
12	oropharynx	base of tongue	T2N1	III	57.75	CDDP 3x
13	oropharynx	tonsil	T4N1	IV	57.75	TPF + carbo weekly
14	oropharynx	base of tongue	T3N0	III	57.75	cetuximab
15	larynx	supraglottis	T3N1	III	57.75	CDDP weekly
16	larynx	supraglottis	T3N0	III	57.75	CDDP 3x
17	larynx	supraglottis	T4N0	IV	57.75	CDDP 3x
18	larynx	supraglottis	T3N0	III	57.75	CDDP 3x
19	hypopharynx	postcricoid	T3N2c	IV	57.75	CDDP 3x
20	hypopharynx	piriform sinus	T4aN2b	IV	57.75	CDDP 3x
21	hypopharynx	piriform sinus	T4N2b	IV	57.75	CDDP 3x
22	oropharynx	tonsil	T2N0	II	54.25
23	oropharynx	base of tongue	T1N1	III	54.25
24	oropharynx	tonsil	T2N0	II	54.25
25	oropharynx	base of tongue	T3N0	III	54.25
26	oropharynx	soft palate	T2N1	III	54.25
27	oropharynx	soft palate	T1N0	I	54.25
28	larynx	transglottis	T2N2b	IV	54.25
29	larynx	glottis	T3N0	III	54.25
30	larynx	supraglottis	T2N0	II	54.25
31	hypofarynx	piriform sinus	T2N1	III	54.25

CDDP: cisplatinum
CDDP 3x: 3 cycles of cisplatinum 100 mg/m²
TPF: docetaxel 75 mg/m² day 1, cisplatinum 75 mg/m²day 1, 5-FU 750 mg/m² day 1-5

ISSN: 1748-717X